Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has earned an average recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $71.40.

Several analysts recently issued reports on ARCT shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a report on Tuesday, October 1st. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 15.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Nordea Investment Management AB bought a new position in Arcturus Therapeutics during the first quarter valued at about $1,846,000. Russell Investments Group Ltd. bought a new position in shares of Arcturus Therapeutics during the 1st quarter valued at approximately $40,000. ProShare Advisors LLC purchased a new stake in shares of Arcturus Therapeutics during the 1st quarter worth approximately $205,000. State Board of Administration of Florida Retirement System raised its holdings in shares of Arcturus Therapeutics by 32.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,841 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 2,160 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its stake in Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

ARCT stock opened at $18.74 on Tuesday. The company’s 50-day moving average is $20.64 and its 200-day moving average is $24.31. Arcturus Therapeutics has a 1 year low of $17.26 and a 1 year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. The firm had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter last year, the firm posted ($1.98) earnings per share. As a group, equities analysts predict that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.